Pulmonary Manifestations of Mantle Cell Lymphoma
Mantle cell lymphoma rarely involves the lungs, but when it does, it presents as pleural effusions, endobronchial lesions with diffuse airway wall thickening, or parenchymal infiltrates; management follows standard MCL systemic therapy protocols rather than lung-specific interventions.
Clinical Presentations
Pleural Involvement
- Recurrent pleural effusions are the most commonly reported pulmonary manifestation, often presenting with exudative lymphocyte-predominant fluid 1, 2.
- Pleural effusions may be the initial presenting feature, accompanied by constitutional symptoms including fever, night sweats, and unintentional weight loss 2.
- Pleural studding and thickened visceral pleura are characteristic imaging findings on CT and PET-CT 1, 3.
- Thoracentesis and pleural fluid cytology are frequently negative for malignancy on initial sampling, requiring more invasive procedures for diagnosis 2.
- Video-assisted thoracic surgery (VATS) or thoracoscopy with pleural biopsy is often necessary to establish a definitive diagnosis when cytology is non-diagnostic 1, 2.
Endobronchial Disease
- Diffuse irregular wall thickening of the trachea and bilateral bronchi is the hallmark of tracheobronchial MCL involvement 4, 5.
- Bronchoscopy reveals a diffuse irregular mucosal surface with polyposis-like lesions throughout the airways 4, 5.
- Patients present with cough and dyspnea on exertion as the predominant respiratory symptoms 4, 5.
- Endobronchial biopsy with immunohistochemical staining (CD5+, CD20+, cyclin D1+) confirms the diagnosis 5.
- Bilateral bronchiectasis may develop secondary to chronic airway involvement 4.
Parenchymal Involvement
- Localized trabecular shadows or nodular infiltrates in the lung parenchyma can occur, though less commonly than pleural or airway disease 1.
- PET-CT demonstrates FDG-avid lesions in affected lung tissue and pleura 1.
Diagnostic Approach
Initial Evaluation
- Contrast-enhanced CT chest or PET-CT is required for staging and identifying pulmonary involvement per Lugano classification 6.
- Pulmonary function testing is recommended before autologous stem cell transplantation (ASCT) in transplant-eligible patients 6.
Tissue Diagnosis
- Immunohistochemistry must demonstrate cyclin D1 positivity, CD5+, CD20+, and CD19+ to confirm MCL 1, 5.
- Flow cytometry of pleural fluid or bronchial washings can identify the characteristic immunophenotype (CD5+, CD10-, CD19+, CD20+, CD25+) 1.
- FISH or PCR for t(11;14)(q13;q32) translocation is mandatory for definitive diagnosis 7.
- Ki-67 proliferation index must be quantified using standardized methods, as it is the most established biological risk factor 6, 7.
Critical Pitfall: Tuberculosis Co-infection
- Patients with MCL are highly vulnerable to tuberculosis, which can present identically to lymphomatous pleural involvement 1.
- Elevated adenosine deaminase in pleural fluid, granulomas, and Langhans giant cells on biopsy suggest concurrent TB 1.
- Always culture bronchial washings and pleural fluid for Mycobacterium tuberculosis in endemic areas or immunocompromised patients, even when MCL is confirmed 1.
- Antituberculosis therapy (rifampicin, isoniazid, pyrazinamide, ethambutol) should be initiated when TB is suspected, as culture confirmation may take 4+ weeks 1.
Management Strategy
Systemic Therapy Takes Precedence
- Pulmonary MCL is managed with systemic therapy identical to nodal disease; there is no lung-specific treatment approach 6, 7.
- Initiate therapy immediately in all symptomatic patients or those with high tumor burden, including those with respiratory compromise from pleural effusions or airway obstruction 7, 8.
Young, Fit Patients (< 65 years, transplant-eligible)
- Intensive cytarabine-containing induction (R-CHOP alternating with R-DHAP, Nordic protocols, or R-hyper-CVAD) followed by ASCT is the standard approach 7, 8.
- High-dose cytarabine significantly prolongs time to treatment failure (P = 0.038) compared to non-cytarabine regimens 7, 8.
- ASCT consolidation improves response rates and overall survival (Level I, Grade B) 7, 8.
- Rituximab maintenance after R-CHOP markedly improves progression-free and overall survival (Level I, Grade A) 7, 8.
Older or Unfit Patients (≥ 65 years, transplant-ineligible)
- Bendamustine-rituximab (BR) is the established standard, providing superior PFS (35 months) versus R-CHOP (21 months) 7.
- VR-CAP (bortezomib + rituximab + cyclophosphamide + doxorubicin + prednisone) yields PFS of 31 months versus 16 months with R-CHOP 7.
- Rituximab maintenance after R-CHOP improves PFS and OS (Level I, Grade A) 7.
High-Risk TP53-Mutated Disease
- BTK-inhibitor–based combinations are strongly recommended, as conventional chemotherapy and ASCT provide limited benefit 7, 8.
- Ibrutinib combined with high-dose cytarabine chemotherapy achieves approximately 96% overall response and 88% complete remission 7, 8.
- Zanubrutinib + obinutuzumab + venetoclax is an alternative regimen with similar efficacy 7.
Supportive Care for Respiratory Complications
- Therapeutic thoracentesis for symptomatic pleural effusions to relieve dyspnea while systemic therapy takes effect 1, 2.
- G-CSF administration during neutropenia from intensive chemotherapy 7, 8.
- Antimicrobial prophylaxis throughout neutropenic periods 7, 8.
- Monitor for tumor lysis syndrome in patients with high pulmonary tumor burden 7, 8.
Role of Radiation Therapy
- Consolidative radiotherapy (30–36 Gy) may be considered for localized pulmonary involvement in limited-stage disease (I–II) after short-course chemotherapy 6, 7.
- RT is not routinely used for advanced-stage pulmonary MCL, as systemic therapy is the priority 6.
Response Assessment
- PET-CT per Lugano criteria should be performed at mid-treatment and end of therapy to assess metabolic response 9, 7.
- Complete metabolic response (Deauville score 1–3) even with residual pleural thickening or lung masses is considered complete remission 9.
- Minimal residual disease (MRD) status is an independent prognostic factor and should be assessed when available 7.